CERS Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$4.50median target· current $2.15 (+109.3%)3 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-0.030.0% YoY
Profit margin-3.1%HEALTHCARE
Market cap$433.3MSmall cap
Valuation
- Forward P/E
- —
- PEG ratio
- 0.00
- P/B
- 6.19
- P/S (TTM)
- 1.96
- EV/EBITDA
- 156.06
Profitability & growth
- ROE (TTM)
- -10.8%
- Operating margin
- -3.2%
- Revenue growth YoY
- 9.5%
- Dividend yield
- —
- Beta
- 1.77
Last earnings
Jul 30, 2026 · Estimate $-0.01 · Reported $-0.01
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Cerus Corporation
Company profileCerus Corporation, a biomedical products company, is focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The company is headquartered in Concord, California.
Classification
- Sector
- Healthcare
- Industry
- Medical Devices
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 1220 CONCORD AVENUE, CONCORD, CA
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$433.3M
Shares outstanding$201.5M
52W high$3.47
52W low$1.15
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent